Skip to main content

Table 1 Relationship between MBD1 expression and clinicopathological factors of patients with GBC

From: MBD1 promotes the malignant behavior of gallbladder cancer cells and induces chemotherapeutic resistance to gemcitabine

Parameter

No. of patients

MBD1 (low)

MBD1 (high)

Spearman correlation

P value

Sex

0.107

0.333

 Male

45

16 (35.6%)

29 (64.4%)

  

 Female

39

10 (25.6%)

29 (74.4%)

  

Age (years)

− 0.020

0.859

 < 60

40

12 (30.0%)

28 (70.0%)

  

 ≥ 60

44

14 (31.9%)

30 (68.1%)

  

Tumor size (cm)

0.085

0.441

 ≤ 5

53

18 (33.9%)

35 (66.1%)

  

 > 5

31

8 (25.8%)

23 (74.2%)

  

Differentiation grade

0.182

0.098

 Well-moderate

31

13 (41.9%)

18 (58.1%)

  

 Poor-undifferentiated

53

13 (24.5%)

40 (75.5%)

  

T stage

0.036

0.742

 T1–T3

56

18 (32.1%)

38 (67.9%)

  

 T4

28

8 (28.6%)

20 (71.4%)

  

Lymph node status

0.378

< 0.001

 Negative

55

24 (43.6%)

31 (56.4%)

  

 Positive

29

2 (6.9%)

27 (93.1%)

  

Distant metastasis status

0.299

0.006

 M0

53

22 (41.5%)

31 (58.5%)

  

 M1

31

4 (12.9%)

27 (87.1%)

  

TNM stage

0.287

0.008

 I–II

34

16 (47.1%)

18 (52.9%)

  

 III–IV

50

10 (20.0%)

40 (80.0%)

  
  1. MBD1 Low: negative/weak MBD1 expression; MBD1 High: moderate/strong MBD1 expression; T stage and TNM stage were defined by the AJCC 8th edition; P-values were derived by Spearman rank correlation; all statistical tests were two-sided